TABLE 2.
Clinicopathologic characteristics for 333 SLN procedures positive by routine H&E, by performance of ALND
| Characteristic | SLN+/no ALND (n = 102), n (%) | SLN+/ALND (n = 231), n (%) | P value |
|---|---|---|---|
| Median age, year (range) | 60 (33–88) | 55 (26–83) | < 0.001 |
| Operation | 0.120 | ||
| Breast conservation | 64 (62.7) | 123 (53.2) | |
| Mastectomy | 38 (37.3) | 108 (46.8) | |
| Completion ALND | |||
| Alone | NA | 151 (65.4) | |
| Simultaneous margin clearance | NA | 80 (34.6) | |
| Median tumor size, cm (range) | 1.4 (0.1–5.0) | 1.5 (0.1–6.0) | 0.356 |
| Tumor size | 0.568 | ||
| T1 (≤2 cm) | 78 (78.8) | 169 (73.8) | |
| T2 (2–5 cm) | 21 (21.2) | 58 (25.3) | |
| T3 (> 5 cm) | 0 (0.0) | 2 (0.9) | |
| Tx (unknown) | 3 | 2 | |
| Histologic grade | 0.546 | ||
| I | 4 (4.7) | 5 (2.5) | |
| II | 28 (32.9) | 64 (31.5) | |
| III | 53 (62.4) | 134 (66.0) | |
| Unknown | 17 | 28 | |
| Nuclear grade | 0.505 | ||
| I | 2 (2.5) | 7 (3.6) | |
| II | 49 (60.5) | 101 (52.6) | |
| III | 30 (37.0) | 84 (43.8) | |
| Unknown | 21 | 39 | |
| LVI present | 25 (24.5) | 98 (42.4) | 0.002 |
| Multicentric/multifocal tumor | 25 (24.5) | 65 (28.1) | 0.593 |
| ER positive | |||
| Present | 82 (82.0) | 190 (82.6) | 0.876 |
| Missing | 2 | 1 | |
| PR positive | |||
| Present | 64 (67.4) | 136 (63.0) | 0.521 |
| Missing | 7 | 15 | |
| Tumor type | 0.447 | ||
| Invasive ductal | 86 (84.3) | 204 (88.3) | |
| Invasive lobular | 11 (10.8) | 19 (8.2) | |
| Microinvasive DCIS | 2 (2.0) | 1 (0.4) | |
| Other invasive carcinomas | 0 (0.0) | 2 (0.9) | |
| Invasive carcinoma with ductal and lobular features | 3 (2.9) | 5 (2.2) | |
| Median year of surgery (range) | 2003 (1997–2006) | 2003 (1997–2006) | 0.904 |
| Median nomogram score, % (range) | |||
| Present | 15 (3–92) | 21 (3–80) | < 0.001 |
| Missing | 7 | 7 | |
SLN sentinel lymph node, H&E hematoxylin and eosin, ALND axillary lymph node dissection, LVI lymphovascular invasion, ER estrogen receptor, PR progesterone receptor, DCIS ductal carcinoma in situ